Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Dr. Jared Weiss is an Associate Professor of Clinical Research for Hematology/Oncology at the University of North Carolina School of Medicine in Chapel Hill, NC. He completed fellowship in Hematology and Oncology at the University of Pennsylvania and residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, MA. He received his Doctor of Medicine at Yale University School of Medicine in New Haven, CT and his B.S. in neuroscience at Brown University, in Providence, RI.
ASCO 2018 Roundtable - Head and Neck Cancer - Attempts to Decrease Toxicity of Chemoradiotherapy
dbrock
Image
Drs. Jared Weiss, Associate Professor, of Medicine, University of North Carolina School of Medicine, and Josh Bauml, Assistant Professor of Medicine, Hospital of the University of Pennsylvania, gathered post meeting to discuss new information from ASCO 2018 regarding head and neck cancers.
In this roundtable video, the doctors discuss attempts to decrease the toxicity of chemoradiotherapy in head and neck cancers.
Please feel free to offer comments and raise questions in our Discussion Forums.
GRACE would like to thank the following sponsor for their support of this program
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists.
To watch the complete playlist, click here.
Image
Video
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format.
To watch the complete playlist, click here.
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
In this 2nd series of videos, Michael Herman takes us through the story of his diagnosis, his struggles with treatment options, his clinical trial and his learning curve.
Thank you to our Sponsors! #lilly #exelixis
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.